MEDI ASSIST HEALTH SERVICESMedi Assist Healthcare Services Limited is a health-tech and insurance-tech company that manages health benefits for employers, retail members, and public health schemes, primarily serving insurance companies.
Company provides third-party administration (TPA) services to insurance companies through its wholly-owned Subsidiaries, Medi Assist TPA, Medvantage TPA, and Raksha TPA. A third-party administrator is an organization that processes health insurance claims for insurance companies and provides services such as policy administration, customer service, and network management, among others.
As of 2023, company collaborated with 35 insurance companies in India and globally. In FY23, company managed a CAGR of 35.67%. The group accounts portfolio as a percentage of revenue from contracts with customers was 72.19% and the retail portfolio was 10.98%.
Company also acts as a facilitator between (a) insurance companies and their policyholders, (b) insurance companies and healthcare providers (such as hospitals), and (c) the Government and beneficiaries of public health schemes.
Company serviced over 9500 group accounts across sectors to help administer the insurance requirements of their employees. It held a significant share of the total health insurance market for group accounts, representing 26.39% of India’s overall group health insurance market in FY23.
Company also services individual insurance policyholders, and for FY23 it managed Rs 17.57 billion of premiums for the retail health insurance market, representing 5.06% of the overall retail health insurance market in India.
In H1FY24, company helped settle 3.05 million claims, comprising 1.37 million in-patient claims and 1.68 million domiciliary or out-patient claims.
Medi assist also facilitates other healthcare and ancillary services such as hospitalization services, call center services, customer relations and contract management services, billing services, and claims processing services through its Company and other Subsidiaries, IHMS, Mayfair India, Mayfair UK, Mayfair Group Holding, Mayfair Philippines, and Mayfair Singapore.
Company has developed a pan-India healthcare provider network, which comprises 18,754 hospitals across 1,069 cities and towns and 31 states (including union territories) in India and a network across 141 countries globally, as of 2023. Company intends to pursue acquisition opportunities to expand its existing service offerings, increase market share in existing markets, and expand to new geographies. In the last eight years, company has completed several acquisitions, including the acquisition of Dedicated Healthcare Services TPA (India), Medicare Insurance TPA Services (India), IHMS, Mayfair India, Medvantage TPA, and Raksha Health Insurance TPA.
Financial Performance:
- Total premiums under management administered by the company was at Rs. 19,050 crores as of March 31, 2024, showing a growth of 30.7% over the previous year.
- Group segment fund was Rs. 16,709 crores, with a growth of 30.4% year-on-year.
- Retail segment stood at Rs. 2,341 crores, showing a growth of 33.2% year-on-year.
- Company's share of the total health insurance industry premium was at 19.6%, with a growth of 186 basis points over the previous year.
Operational Highlights:
- Maintained group account retention at 94.7%.
- Processed 3.6 million outpatient claims in the last year.
- Won an award for "Best use of AI in Healthcare" for the Fraud Detection Engine.
- Continuing to invest in preventing fraud, waste, and abuse in the system.
- Building a team of data scientists for better data security and analytics.
Financials:
- Total income for the quarter ended March 31, 2024, was Rs. 171 crores, showing a growth of 23% year-on-year.
- EBITDA for the quarter was INR 37 crores, with a margin of 22% on operating revenue.
- Profit after tax stood at Rs. 25 crores, showing a growth of 50% year-on-year.
- Total income for the year ended March 2024 was Rs. 653 crores, with a growth of 26% over the previous year.
- EBITDA for the year was Rs. 133 crores, with a margin of 21% on the operating revenue.
- Profit for the period, adjusting for exceptional items, was Rs. 92 crores, showing a growth of 22% year-on-year.
Technology and Investment:
- Investing around 3-4% of revenues every year in technology.
Total investment in the platform and capitalization as of March 31, 2024, was Rs. 10 crores.
- Investing in a platform for the UK, with an expected cost of around 8 crores.
Future Outlook:
- Expecting to bring the acquisitions to the company's margin profile in the next 2-3 quarters.
- Focused on enhancing insurer relationships and expanding benefits in the retail segment.
- Cashless facility being expanded to non-network hospitals for emergency access.
- Strong emphasis on technology for service delivery and customer retention.
Challenges and Opportunities:
- Opportunities seen in expanding the retail market share and leveraging technology for growth.
- Optimistic outlook expressed by the management regarding future prospects and growth potential.
Growth
Craftsman Automation - Cup & Handle PatternCraftsman automation is into automobile industry. It has moved out of cup & handle breakout and should move towards our target. Other factors:
1. Fundamentally great stock
2. Recent acquisitions shows growth
3. FII & DIIs has increased stake
4. RSI positive
5. MACD positive
Keep following Cleaneasycharts.
Right Stock at Right Time at Right price.
Cheers!!!
PETRONET LNG RANGE BOUND SETUPThe stock has been consolidating in a range for a quite a long period of time moreover this stock can be a perfect example for range bound trading the range begun in the 2017 year and is still prevailing the 190 levels have been a crucial support zone for the stock and a solid rebound happens everytime it touches that level on the upper side the 271 levels has been a major resistance for the stock if this is broken than a prolonged rally till 350 lvls can be witnessed. additionally if we look at the fundamentals of the stock it shows quite a promising side , the
PE-9.99
PROFIT - HIGHEST EVER
This is the cheapest valued stock in the gas distribution sector and has a growing and a promising future and demand
Scanner shows - IRFCKeeping the faith on my scanner and investing in its throwup, i have decided to put in money on IRFC today, hoping to make good as my last trade. (though did not put in other two power sector companies which my scanner had given; and they did make good money). This is a swing trade - few days to a month or so holding period.
Buy Mankind Pharma for major upside . 2 lakh to 2 Cr journey Cmp 2300
Buy near 2280
short term target 2408 &2495
Now take a look of Long term journey
Mankind Pharma cam be a multibagger counter
5 years Sales, profit and return of equity growth almost more than 20% and this can be increase more and more .
Counter going to reach at 1 lakh cr capital this year and after that it will unstoppable .
100% debt free company
All the parameter are perfect for long term selection .
Just invest 2 lakh in this counter during upcoming 2 years and sleep relax...
After 20 years your 2 lakh will become 2 cr.
We personally start investing in this counter .
If you dont have 2 lakh then you can follow 5000Rs SIP for 40 months
You can earn with trading but if you want to create a wealth then long term investing is only solution .
Dont miss this opportunity .
Natco Pharma, the road ahead?Its been a journey of parallel channels for Natco Pharma share price and one believes that it will continue to tread within the broad confines of the longer term monthly channel
Price has now found the resistance area of the channel which started from the lows of the covid (in blue). However, with the earnings on lenalidomide still some 15-18 months away from reaching peak levels, atleast in volume terms, by that time the street should hear expected positive news on some of the points listed below:
- new successful para IV filings and launches from existing tentative or final approved list,
- fixing the usfda cloud over kothur formulations plant,
- traction on the much anticipated brownfield acquisition,
- their CAR T investment growing into something tangible in value terms,
- substantial increase in foreign subsidiary business
- domestic formulation sales getting boost due to possible semalglutide launch
- scaling up of crop health science business
therefore looking at the hanging man on WCB I believe that whether for profit booking or geo political or general broader market sentiment it can correct in the immediate shorter term, however, the bullish thesis remains for the fundamental reasons enumerated above.. The first target from here seems to be around 2500 which can be plotted either by box breakout (from 2017 highs) or a rounding bottom (from 2021 highs) or simply the width of the blue parallel channel if and when it breaks out...
The principle of polarity suggests that price may not close below the line plotted by taking the highs of 2017 and 2021 (the pink dotted line) this area should be our longer term stop loss and a time to revisit the bullish thesis.
Great opportunity 20% discounted price.The stock is undervalued here is why--
> Company's profit is growing on a fast phase while the stock is not growing that much
this results that stock is still underpriced. The stock is almost 20% down from its all
time high.
> The Central Electricity Authority (CEA) estimates India’s power requirement to grow to reach
817 GW by 2030.
> TATA POWER is the leading company in solar rooftop and 102 MW orders won in Q1 FY25
Thyrocare Technologies in Buying Zone with Strong Sales GrowthNSE:THYROCARE Thyrocare Technologies has shown a strong breakout after a long period of consolidation, supported by robust sales growth and consistent profitability. The stock is in a buying zone with strong volume, presenting a promising opportunity for investors.
Fundamentals:
Strong sales growth
Good dividend player
Consistent profitable growth
Technical:
Strong volume peak after consolidation, indicating potential buying interest
Stock is in a buying zone
May retest, so consider buying in small lots
Good liquidity
Cables next rallyIndustry is experiencing robust demand environment and Polycab is well-positioned to capitalize on this favourable market dynamics.
India Ratings has improved the outlook on Polycab's credit rating to “positive” from the earlier “on watch with negative implication”
Polycab's in the process of calibrating new mid-term guidance and will be releasing the new guidance during the course of this financial year
RDSS Govt scheme will give good orderbook
Polycab working on 4 areas
Improving our reach
Product development
Brand positioning
Influencer management
Every quarter, Polycab adding new geography to supply its inventory
Working on 1000 to 1100cr capex to cater increased demand in next few years. 280Cr capex already done.
Capacity utilization in Q1 70-75%
In power transmission distribution sector, component of cable supply is high than other sectors. Cables 75% and wires 25% contribution.
Wire contribution would increase in upcoming quarters between 4 to 8 as real estate projects are in progress.
Framed index with Kei, Polycab, RRkabel, Fincables. Fib target is double of current. Target 29987.45 of this index.
$NSE:GLOBE: Still NOT TOO late to BUYSummary:
NSE:GLOBE Globe Textiles exhibits strong fundamentals with a high Piotroski score of 8 and is trading at a reasonable PE ratio of 15. The stock has shown a strong technical breakout with significant volume, indicating potential for further upside.
Fundamentals:
Very strong fundamentals
High Piotroski score of 8
Currently trading at a PE ratio of 15
High-performing player in the textiles industry
Technical:
Strong volume peak after consolidation, indicating potential institutional buying
Strong breakout, still not too late to buy
Good liquidity
Trade Setup:
Entry: Current Market Price
Stop Loss: Conservative stop loss level based on recent support (4.50)
Potential Upside: 8.50 NSE:GLOBE
Trident 37.75 - Profit Making opportunity (30% to 50%) or moretrident has been consolidating for while and it was in sideway trend.
by looking at volumes and deliverable quantities stock is expected to move upside.
it shows buyer's are interested to buy this stock and its shows strong buy signal.
1. if stock breaks 42 we might see it move up to Rs 51
2. Best buy around 37 to 38 stoploss 35.50
Canara Bank 113.86 - Best Swing Trade 5 to 10%Stock will trade between 106.50 to 122.
By looking at recent data stock has split and has given dividend.
looking at volumes and deliverable quantity is around 40-50% stock might trade between 106 to 122.
once stock breaks 124 we might see stock move up to RS.141
ESAF Small finance 50.73 - Buying Opportunity 30-40% returnsESAF is almost trading at 52 weeks low and company is paying Rs .70 dividend.
The company's balance is good and stock can give good returns in coming days.
There's good support at 49 levels and RSI is in Oversold zone. if the stock price is around 49 and rsi is above 30 then buy stocks and exit once your target reached.
Long term perspective stock could give up to 50% return
KOTAK BANK - A Value Buying Pick for Long Term Investors?Symbol - KOTAKBANK
CMP - 1755
Kotak Mahindra Bank is a diversified financial services group providing a wide range of banking and financial services including Retail Banking, Treasury and Corporate Banking, Investment Banking, Stock Broking, Vehicle Finance, Advisory services, Asset Management, Life Insurance and General Insurance.
This is one among India's top banks.
Currently trading at lowest valuation in last 10 years which makes it a great value buying pick at current levels.
Stock has gone nowhere in last 3.5 years and consolidating in a range.
1700 Level is a long term support. It can be added at current levels and If 1720-1700 comes, can be added more.
Long term targets comes around 2500 level which is almost 50% upside from here.
South India Bank 26.90 - 30%-40% return in short term South India bank is fundamentally strong stock.
Revenue has increased over the period and also the profits.
Institutional investors are eyeing on this stock and coming days might witness sudden move
in price.
if any big institution or securities broker recommends the stock than i would wait for 15days
and buy it later.
Target of Rs 32 - 33